Incyte Corporation (INCY)

54.83 -0.13 (-0.24%) As of 10:01AM EST. Market open.

Incyte Corporation

1801 Augustine Cut-Off
Wilmington, DE 19803
United States
302 498 6700
https://www.incyte.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2,324

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Herve Hoppenot	CEO & Chairman	2.89M	N/A	1960
Ms. Christiana Stamoulis MBA	Executive VP & CFO	1.16M	N/A	1971
Dr. Barry P. Flannelly M.B.A., Pharm.D.	Executive VP & GM of North America	996.28k	545.65k	1958
Dr. Steven H. Stein M.D.	Executive VP & Chief Medical Officer	1.22M	N/A	1967
Dr. Pablo J. Cagnoni M.D., Ph.D.	President and Head of Research & Development	N/A	N/A	1963
Mr. Thomas Tray	VP of Finance, Chief Accounting Officer & Controller	N/A	N/A	1978
Mr. Michael James Morrissey	Executive VP & Head of Global Technical Operations	N/A	N/A	1964
Ms. Christine Chiou	Head of Investor Relations	N/A	N/A	N/A
Sheila A. Denton	Executive VP & General Counsel	N/A	N/A	N/A
Ms. Pamela M. Murphy	Vice President of Investor Relations & Corporate Communications	N/A	N/A	1951

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Corporate governance

Incyte Corporation’s ISS governance QualityScore as of 1 December 2023 is 8. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.